Cyclacel Phar Pr SEC Filings

Kua Khai Loon, identified on the form as a Director, reported a sale of 19,054 shares of Cyclacel Pharmaceuticals common stock on 09/05/2025 at a price of $7.01 per share. After the reported transaction the filing shows 385,411 shares beneficially owned, held directly. The Form 4 is signed and dated 09/10/2025. The filing discloses the transaction type as a sale and provides the transaction price and post-transaction holdings; no derivative transactions or additional explanatory details are included.

Yap Kim Choy, a director of Cyclacel Pharmaceuticals, Inc. (CYCC), exchanged Series C Common Stock Purchase Warrants for common shares on September 4, 2025. The reporting person exchanged 186,465 Series C warrants under a warrant exchange agreement dated September 4, 2025 and received 186,465 shares of Common Stock in return. After the transaction, the reporting person beneficially owned 404,465 shares of Common Stock and held 31,535 Series C warrants remaining. The filing is a Section 16 Form 4 reporting this non-derivative acquisition and related derivative changes.

Kua Khai Loon, a director of Cyclacel Pharmaceuticals, Inc. (ticker CYCC), reported on 09/04/2025 that he exchanged 186,465 Series C Common Stock Purchase Warrants for 186,465 shares of common stock under a warrant exchange agreement. After the transaction he beneficially owns 404,465 shares of common stock and directly holds 31,535 Series C warrants remaining. The filing indicates the exchange was recorded under transaction code J(1) and shows the warrants had a $10.20 conversion/exercise price and expire on 06/20/2030. This Form 4 documents the insider conversion of derivative securities into common equity.

Ong Yee Lung, a director of Cyclacel Pharmaceuticals, filed a Form 4 reporting that on 09/04/2025 he exchanged 186,465 Series C Common Stock Purchase Warrants for 186,465 shares of Common Stock pursuant to a warrant exchange agreement dated the same day. After the transaction, the reporting person beneficially owned 404,465 shares of Cyclacel common stock. The filing is signed and dated by the reporting person and indicates the change resulted from an exchange under the specified agreement.

Ong Yee Lung reports beneficial ownership of 20.76% of Cyclacel Pharmaceuticals, Inc.'s common stock class. The filing states he holds an aggregate of 872,000 instruments comprised of 218,000 common shares and three series of warrants — 218,000 Series A, 218,000 Series B and 218,000 Series C — each exercisable into common stock. The filing indicates sole voting and dispositive power over the aggregate amount and affirms the holdings were not acquired to change or influence control of the issuer.

Kua Khai Loon reports beneficial ownership of 872,000 shares of Cyclacel Pharmaceuticals, Inc., representing 20.76% of the outstanding common stock. The reported ownership is composed of 218,000 shares of common stock and 218,000 warrants in each of three series (Series A, B and C), each exercisable into common stock, for a total of 872,000 underlying shares. The filing certifies the holdings were not acquired to change or influence control of the issuer. The report includes links to the amended and restated warrant forms as exhibits.

Yap Kim Choy filed an amendment on Schedule 13G reporting beneficial ownership in Cyclacel Pharmaceuticals, Inc. common stock totaling 872,000 shares or equivalents, representing 20.76% of the class. The filing states the position consists of 218,000 common shares and 218,000 warrants in each of three series (A, B and C) that together account for the aggregate amount. The filer reports sole voting and dispositive power over the full amount and certifies the securities were not acquired to change or influence control of the issuer. The filing includes links to the amended and restated warrant forms as exhibits.